SPECT-CT imaging with $[^{99m}Tc]$PSMA-T4 in patients with recurrent prostate cancer

Sonya Sergieva¹, Radoslav Mangaldgiev², Milena Dimcheva¹, Kamen Nedev³, Zahary Zahariev⁴, Bozhil Robev⁵

¹Department of Nuclear Medicine, Sofia Cancer Centre, Sofia, Bulgaria
²Department of Medical Oncology, Sofia Cancer Centre, Sofia, Bulgaria
³Department of Radiotherapy, Acibadem City Clinic, Sofia, Bulgaria
⁴Department of Radiotherapy, UniHospiatal, Panagyurishte, Bulgaria
⁵Department of Medical Oncology, UH “St Ivan Rilsky”, Sofia, Bulgaria

[Received 12 II 2021; Accepted 19 VII 2021]

Abstract

Background: Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with overexpression of the prostatic tumour cells. Several small molecules of PSMA ligands of inhibitors binding to the active site of PSMA were developed. $[^{99m}Tc]$Tc-PSMA-T4 is a new radiopharmaceutical (Polatom) for imaging loco-regional metastases and/or local relapse in patients with prostate cancer.

The purpose of this work was to evaluate the clinical application of SPECT-CT imaging with $[^{99m}Tc]$Tc-PSMA-T4 in patients with recurrent prostate cancer.

Material and methods: Thirty-six patients with prostate cancer, aged 60–80 years with biochemical relapse of PSA (ranged from 0.1 to 73 ng/mL) were included. Three patients were studied after tru-cut biopsy, hormonal and cytoreductive radiotherapy and 33 patients out of 36 — after radical treatment (total prostatectomy or definitive radiotherapy of the tumour). All of them underwent whole-body imaging examinations with subsequent target SPECT-CT studies of the pelvis, abdomen and/or chest, 1–3 hrs post i.v. administration of $[^{99m}Tc]$Tc-PSMA-T4. The average activity dose was 6.3 MBq/kg in a man of 70 kg. A Dual-head SPECT-CT gamma camera with a low dose CT scan (Symbia T2, Siemens) was used. The images were interpreted based on all other clinical and radiological data. Follow-up could be conducted in 11/36 patients during that period.

Results: Normal biodistribution of the radiopharmaceutical with high activity background was observed in the liver, spleen, kidneys, lacrimal and salivary glands, bowels and urinary bladder. Positive imaging for local relapse in the prostate bad was imaged in 21 patients, lymph node metastases — in 16 cases, bone lesions — in 10 cases, pulmonary metastases — in 2 cases, hepatic lesions were visualised in one of them and in another — adrenal suprarenal metastasis with intensive tracer uptake significant for overexpression of PSMA. There was a suspicion for local recurrences in 4 patients with negative MRT studies who were followed up. In 3 cases, previously treated bone metastases were partially negative without tracer uptake, only some progressive bone lesions were positive. Five patients were with negative results. Sensitivity was 84.37% (27/32), specificity — 100% (4/4) and accuracy — 86.11% (31/36).

Conclusions: In conclusion SPECT-CT imaging with $[^{99m}Tc]$Tc-PSMA-T4 could be applied in patients with prostate cancer for the diagnosis of recurrent disease to determine personalized treatment for each patient. Specific uptake of this tracer, depicted by SPECT-CT images has clinical importance of identifying and assessing PSMA expression before consideration of Radio Ligand Therapy (RLT) with $[^{177}Lu]$Lu-PSMA. SPECT-CT imaging with $[^{99m}Tc]$PSMA is promising and reliable nuclear medicine approach to monitoring therapeutic effect after treatment and for restaging of the disease.

KEY words: recurrent prostate cancer; PSMA; $[^{99m}Tc]$Tc-PSMA-T4; SPECT-CT

Nucl Med Rev 2021; 24, 2: 70–81
Introduction

Prostate cancer is the most common malignancy in men in Europe. According to forecast statistics for 2018, the number diagnosed with this disease is 450,000 men or 20% of all cases of malignancies in them [1]. This disease is socially significant both in Bulgaria and in the countries of the European Union. The incidence in 2018 (standardized indicator per 100,000 men) varies from 80.2 in Romania to 265.2 in Ireland. In Bulgaria, the incidence is 136.4, 14% lower than the European Union average, but with a tendency to increase. Mortality in 2018 varies from 22.7 in Italy to 73.9 in Estonia. In Bulgaria, the mortality rate is 40.1 and is 7% higher than the average for the European Union, with a tendency to increase, and the survival rate is the lowest among the European — 68% [1, 2]. Interpretation of these factual data points out that modern diagnostic and therapeutic methods have not yet shown their impact on epidemiological indicators in Bulgaria as well as in some other European countries. The reasons for this are complex and diverse for different countries.

One of the important clinical problems is the early detection and visualization of recurrences after prostatectomy, radiotherapy or other definitive local treatment, with PSA values above 0.2 ng/mL. Contrast-enhanced magnetic resonance imaging (MRI) and computed tomography (CT) scans are most commonly used, but they are not always of sufficient sensitivity and specificity, especially at low tumour marker values [3, 4].

With the introduction of molecular high sensitive imaging after administration of radiolabelled prostate-specific membrane antigen (PSMA), it has become possible to obtain early functional information for disease development and recurrence detection, which is more accurate than that of CT or MRI in many cases [5, 6].

Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with overexpression of the prostatic tumour cells. This membrane antigen is known as glutamate carboxypeptidase II (GCP II), a membrane-bound binuclear zinc metallopeptidase, which is available in low concentrations in normal kidney, intestinal tissue and salivary glands [7, 8]. PSMA overexpression is observed also in endothelial cells of tumour neovasculature of non-prostatic solid tumours and benign lesions: colon, gastric, breast, thyroid, ovary, Paget Disease, probably stimulated by secreted angiogenic factors. Upon ligand binding, PSMA is internalized via endocytosis in the tumour cell [7, 8].

In recent years in the clinical practice, a new concept was introduced for specific diagnosis and targeted effective radionuclide treatment of metastatic prostate cancer (PC) after administration of a target PSMA molecule, labelled with various radionuclides, on the principles of theranostics [9, 10].

The degree of intensity of PSMA overexpression epithelial cells in PC is proportional to the degree of malignant cell differentiation and metastatic spread [7, 8]. The field of radiopharmacy and radiochemistry over the last decade is focused on the development of small ligand molecules or binding inhibitors with the active PSMA core, which are characterized by high specificity, good permeability in solid tumours, optimal pharmacokinetics in normal tissues, easily labelled and synthesized, no host-immune response in the recipient [7, 8].

Such PSMA ligands can be labelled with different radionuclides, respectively with $^{68}$Ga, $^{18}$F, $^{99m}$Tc, $^{123/124}$I (emitting positron or gamma emission) for diagnostic purposes or with $^{177}$Lu, $^{131}$I, $^{225}$Ac (emitting beta or alpha emissions) to conduct target radioligand therapy. The most used diagnostic radiopharmaceutical is the $^{90}$Ga PSMA-11 inhibitor [6, 8, 10].

After intravenous application of gamma-emitting radiopharmaceutical $^{99m}$TcPSMA or positron-emitting $^{68}$GaPSMA, positive scans were significant for the presence of PSMA overexpression, this information is important for the assessment of malignant lesions and disease extension [5, 6].

Several small molecules of PSMA ligands or inhibitors were developed. One such small ligand binding to the active site of PSMA, namely PSMA-T4 (Glu-CO-Lys-L-Trp-4-Amc-HYNIC) and the kit formulation for its radiolabelling with technetium-99m resulting in the $^{99m}$TcPSMA-T4radiopharmaceutical were developed at Radioisotope Centre Polatom, National Centre for Nuclear Research in Otwock, Poland.

The purpose of this study was to evaluate the clinical role of $^{99m}$TcPSMA-T4 for imaging of local relapse and/or loco-regional and distant metastases in patients with recurrent prostate cancer and biochemical disease progression.

Material and methods

Patients

This was a prospective study conducted in the period January 2019 — January 2020 after preliminary approval of this scientific project on the Local Ethics Committee. A cohort of 36 patients, aged 60–80 years/average of 69.44 years/ with prostate cancer was examined after obtaining written informed consent. Three patients underwent tru-cut biopsy, hormonal and cytoreductive radiotherapy; 33 patients out of 36 received radical treatment of primary cancer (total prostatectomy or definitive radiotherapy of the tumour). There was laboratory data on biochemical disease progression — serum value elevation of the tumour marker PSA and its doubling within 6 months. The average serum PSA level before SPECT-CT imaging was 6.73 ng/mL (ranged from 0.1 to 73 ng/mL) (Tab. 1).

All of the patients underwent whole-body imaging examinations with target SPECT-CT studies 1–3 hrs post intravenous administration of $^{99m}$TcPSMA-T4.

Radiolabelling

PSMA-T4 (Glu-CO-Lys-L-Trp-4-Amc-HYNIC, 23 mcg) in the form of a dry kit for radiolabelling with technetium-99m has been obtained from National Centre for Nuclear Research (Polatom, Poland) and was radiolabelled with technetium-99m according to the procedure: to the kit vial, 1 to 2.5 mL of sodium pertechnetate solution (eluate from the $^{99}$Mo/$^{99m}$Tc generator) with radioactivity in the range from 370 to 1500 MBq was added. The content of the vial was gently mixed for 30 seconds to allow complete dissolution, then heated in the boiling water bath for 15 min and afterwards cooled down at room temperature for 10 min. Radiolabelling yield was more than 95% as assessed by instant thin-layer chromatography (ITLC). The complex $^{99m}$TcPSMA-T4 was stable for not less than 4 h.

The average activity dose injected intravenously was 6.3 MBq/kg in a man of 70 kg.
### Table 1. Clinical and pathological characteristics of the 36 patients with biochemical recurrence of prostate cancer

<table>
<thead>
<tr>
<th>Pt No/Age</th>
<th>TNM Stage</th>
<th>Gleason Score</th>
<th>PSA at SPECT-CT Image</th>
<th>Primary Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/67 years</td>
<td>pT3bpN1M0</td>
<td>7 (4 + 3)</td>
<td>0.271 ng/mL</td>
<td>RP, RT, ADT</td>
</tr>
<tr>
<td>2/73 years</td>
<td>T3N0M0</td>
<td>7 (4 + 3)</td>
<td>12 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>3/71 years</td>
<td>T3N0M0</td>
<td>8 (4 + 4)</td>
<td>73 ng/mL</td>
<td>RT, ADT, Chemotherapy</td>
</tr>
<tr>
<td>4/68 years</td>
<td>pT2pN0M0</td>
<td>7 (4 + 3)</td>
<td>0.30 ng/mL</td>
<td>RP</td>
</tr>
<tr>
<td>5/87 years</td>
<td>T3N1M0</td>
<td>9 (5 + 4)</td>
<td>9.68 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>6/64 years</td>
<td>T3bN1M0</td>
<td>9 (5 + 4)</td>
<td>2.15 ng/mL</td>
<td>Cytoreductive RT, ADT, Chemotherapy</td>
</tr>
<tr>
<td>7/63 years</td>
<td>pT2pN0M0</td>
<td>7 (3 + 4)</td>
<td>0.12 ng/mL</td>
<td>RP</td>
</tr>
<tr>
<td>8/65 years</td>
<td>pT3pN0M0</td>
<td>6 (3 + 3)</td>
<td>0.36 ng/mL</td>
<td>RP</td>
</tr>
<tr>
<td>9/70 years</td>
<td>pT2pN0M0</td>
<td>7 (3 + 4)</td>
<td>0.24 ng/mL</td>
<td>RP, RT</td>
</tr>
<tr>
<td>10/64 years</td>
<td>pT2cpN0M1</td>
<td>7 (4 + 3)</td>
<td>0.82 ng/mL</td>
<td>RP, ADT</td>
</tr>
<tr>
<td>11/70 years</td>
<td>pT2pN0M0</td>
<td>7 (4 + 3)</td>
<td>0.69 ng/mL</td>
<td>RP, ADT</td>
</tr>
<tr>
<td>12/79 years</td>
<td>T3N0M0</td>
<td>10 (5 + 5)</td>
<td>10.87 ng/mL</td>
<td>RT, ADT, Chemotherapy</td>
</tr>
<tr>
<td>13/60 years</td>
<td>pT2pN0M0</td>
<td>5 (3 + 2)</td>
<td>0.50 ng/mL</td>
<td>RP</td>
</tr>
<tr>
<td>14/64 years</td>
<td>T3aN0M0</td>
<td>7 (4 + 3)</td>
<td>0.16 ng/mL</td>
<td>RP, ADT</td>
</tr>
<tr>
<td>15/74 years</td>
<td>pT3bpN1M0</td>
<td>9 (5 + 4)</td>
<td>0.35 ng/mL</td>
<td>RP, RT, ADT, Chemotherapy</td>
</tr>
<tr>
<td>16/75 years</td>
<td>pT2cpN0M0</td>
<td>7 (4 + 3)</td>
<td>0.57 ng/mL</td>
<td>RP, RT, ADT</td>
</tr>
<tr>
<td>17/75 years</td>
<td>pT2cpN0M0</td>
<td>7 (4 + 3)</td>
<td>0.36 ng/mL</td>
<td>RP</td>
</tr>
<tr>
<td>18/70 years</td>
<td>T3bN0M1</td>
<td>7 (3 + 4)</td>
<td>58 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>19/62 years</td>
<td>T3bN1M1</td>
<td>8 (4 + 4)</td>
<td>0.66 ng/mL</td>
<td>Cytoreductive RT, ADP</td>
</tr>
<tr>
<td>20/66 years</td>
<td>T2N0M1</td>
<td>7 (4 + 3)</td>
<td>0.41 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>21/63 years</td>
<td>T3aN0M0</td>
<td>7 (4 + 3)</td>
<td>1.78 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>22/77 years</td>
<td>pT2pN0M0</td>
<td>7 (3 + 4)</td>
<td>1.5 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>23/69 years</td>
<td>T2N0M0</td>
<td>7 (4 + 3)</td>
<td>7.3 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>24/79 years</td>
<td>pT2pN0M0</td>
<td>6 (3 + 3)</td>
<td>1.42 ng/mL</td>
<td>RP, RT, ADT</td>
</tr>
<tr>
<td>25/64 years</td>
<td>T4N1M1a</td>
<td>8 (4 + 4)</td>
<td>14 ng/mL</td>
<td>RT, ADT</td>
</tr>
<tr>
<td>26/77 years</td>
<td>T3aN0M0</td>
<td>7 (3 + 4)</td>
<td>0.8 ng/mL</td>
<td>RT</td>
</tr>
<tr>
<td>27/66 years</td>
<td>T2N0M0</td>
<td>8 (4 + 4)</td>
<td>1.88 ng/mL</td>
<td>RT</td>
</tr>
<tr>
<td>28/69 years</td>
<td>pT2pN0M0</td>
<td>7 (4 + 3)</td>
<td>0.25 ng/mL</td>
<td>RP, RT</td>
</tr>
<tr>
<td>29/60 years</td>
<td>pT2pN0M0</td>
<td>5 (3 + 2)</td>
<td>0.77 ng/mL</td>
<td>RP, ADT</td>
</tr>
<tr>
<td>30/78 years</td>
<td>T1cN1M1</td>
<td>8 (4 + 4)</td>
<td>27 ng/mL</td>
<td>RT, ADP</td>
</tr>
<tr>
<td>31/69 years</td>
<td>pT2N0M0</td>
<td>5 (3 + 2)</td>
<td>1.6 ng/mL</td>
<td>RP, ADP</td>
</tr>
<tr>
<td>32/70 years</td>
<td>pT2N0M0</td>
<td>7 (4 + 3)</td>
<td>0.23 ng/mL</td>
<td>RP, RT</td>
</tr>
<tr>
<td>33/73 years</td>
<td>T4N1M0</td>
<td>9 (4 + 5)</td>
<td>0.30 ng/mL</td>
<td>Cytoreductive RT, ADP</td>
</tr>
<tr>
<td>34/80 years</td>
<td>T2N0M0</td>
<td>7 (4 + 3)</td>
<td>5.90 ng/mL</td>
<td>RT, ADP</td>
</tr>
<tr>
<td>35/70 years</td>
<td>pT3bpN0M0</td>
<td>8 (4 + 4)</td>
<td>1.72 ng/mL</td>
<td>RP, ADP</td>
</tr>
<tr>
<td>36/71 years</td>
<td>pT2cpN0M0</td>
<td>8 (5 + 3)</td>
<td>0.47 ng/mL</td>
<td>RP, ADP</td>
</tr>
</tbody>
</table>

RP — radical prostatectomy; RT — radiotherapy; ADT — androgen deprivation therapy

### Imaging protocol

Whole-body imaging examinations with subsequent target SPECT-CT studies of the pelvis, abdomen and/or chest and were carried out 1–3 hrs. after tracer application. SPECT-CT gamma camera Symbia T2, Siemens, was used for topographic localization and morphological substratum of “hot” abnormal foci. Dual-head SPECT acquisition included 64 projections, 25 s/projection, matrix 256 × 256. A low dose CT scan was performed in the helical mode. Acquisition parameters included settings at 130 kV, 30 mA, 3–5 mm slice thickness.

SPECT-CT images were analysed considering any focal abnormal uptake of $[^{99mTc}]$Tc-PSMA-T4 above the surrounding background level, not associated with physiological biodistribution, suggestive of malignancy. The diagnostic differentiation between malignant and inflammatory lymph nodes is based not only on the intensity of tracer accumulation but also on the morphological structure of the nodule and the anatomical localization, especially if the accumulation is bilaterally symmetrical in the inguinal, hilar or axillary lymph nodes. The obtained SPECT-CT results were compared with the data from the
previously conducted diagnostic imaging studies — computed tomography, magnetic resonance tomography, bone scintigraphy. The images were interpreted based on all other clinical and radiological data.

Follow-up SPECT-CT studies with $^{99mTc}$Tc-PSMA-T4 were performed in 11/36 patients to monitor and evaluate the results of baseline scans and conducted treatment.

**Results**

Normal biodistribution of the radiopharmaceutical with high activity background was observed in the liver, spleen, kidneys, lacrimal and salivary glands, oral and nasal mucosa, bowels and urinary bladder (Fig. 1).

Positive imaging for local relapse in the prostate bed was imaged in 21 patients, pelvic and extra pelvic lymph node metastases — in 16 cases, bone lesions — in 10 cases, visceral lesions — in 3 cases: pulmonary metastases — in 2 cases, hepatic and adrenal suprarenal metastases — in one of them (Fig. 2–7). The smallest visualized positive lymph node was axial in size 9.2 mm (Fig. 2). All abnormal “hot” spots were scanned with intensive tracer uptake significant for PSMA overexpression.

There was a suspicion of local recurrence in the prostate bed in 4 patients with negative MRT imaging who were followed up after 6 months. The presence of the pathological findings was confirmed by the performed control studies with $^{99mTc}$Tc-PSMA-T4, as they were also positive by the computed tomography or magnetic resonance imaging carried out in parallel.

In 4 patients negative results were obtained for local recurrence of the prostate, no lymphogenic spread or hematogenous dissemination of the disease was observed. In these cases, the level of the tumour marker PSA decreased in the control studies, for these reasons, the data from the imaging $^{99mTc}$Tc-PSMA-T4 study were interpreted as truly negative (Fig. 4).

In 3 cases with multiple bone metastases, treated palliatively with radiotherapy and osteomodulators, tracer uptake was found only in some progressive bone lesions. There was a lack of activity in most osteosclerotic foci, probably due to a suppressed osteoblastic process after treatment (Figure 7). In one of these patients, the study with $^{99mTc}$Tc-PSMA-T4 was performed to exclude visceral and lymphogenic dissemination of the disease to plan treatment with Xofigo infusion (Fig. 8).

Targeted radiotherapy was performed in seven patients with a positive result for the development of local recurrence in the prostate.
Figure 2. M/64yr with prostate cancer, pT3bpN1Mo, G3, Gl = 9 (5 + 4). Cytoreductive radiotherapy (01/2018), androgen deprivation therapy, chemotherapy. PSA = 2.157 ng/mL (01/2019). Whole-body scan and target $[^{99m}Tc]$Tc-PSMA-T4 SPECT-CT imaging showed local recurrence and enlarged bilateral obturator lymph nodes, common iliac lymph node on the right, periaortic with diameter 9.2 mm lymph node, paraesophageal retrotracheal lymph node and supraclavicular lymph node metastases with intensive tracer uptake.

Figure 3. M/71yr with prostate cancer T3N0M0, G3, Gl = 8 (4 + 4). Radiotherapy definitive (09/2013). Androgen deprivation therapy. Chemotherapy and osteomodulators. PSA = 73ng/mL (02/2019). Whole-body scan and target $[^{99m}Tc]$Tc-PSMA-T4 SPECT-CT imaging showed multiple bone metastases and enlarged retroperitoneal lymph node metastases with intensive tracer uptake.
Figure 4. M/73yr with prostate cancer, T4N1M0, G3, GI = 9 (4 + 5). Cytoreductive radiotherapy (03/2019) and androgen deprivation therapy. PSA = 0.30 ng/mL (06/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed enlarged prostatic gland and perivesical lymph nodes with intensive tracer uptake corresponding to MRT images. Disease persistence

Figure 5. M/70yr with prostate cancer, pT2N0M0, G2, GI = 7 (3 + 4). Radical prostatectomy (2017) and radiotherapy. PSA = 0.24 ng/mL (06/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed local recurrence in the prostatic bed with intensive tracer uptake. Disease progression
Figure 6. M/67yr with prostate cancer, pT3bpN1M0, GI = 7 (4 + 3). Radical prostatectomy, radiotherapy (01/2018) and androgen deprivation therapy. PSA = 0.27 ng/mL (01/2019). Whole-body scan and target $[^{99mTc}]$Tc-PSMA-T4 SPECT-CT imaging showed enlarged mediastinal lymph node metastases with intensive tracer uptake.

Prostate bed and pelvic lymphadenopathy. SPECT-CT images were used for contouring the gross tumour volume (GTV) and the clinical tumour volume (CTV) in the radiotherapy planning (Fig. 9, 10).

Negative results were found in 5 patients. They were followed up after 6 months, and no pathological lesions with tracer uptake were visualized in the second study. In this group, a continuing increase in serum PSA was observed:

- In the first patient, the value of PSA before the baseline $[^{99mTc}]$Tc-PSMA-T4 study was 0.12 ng/mL and 6 months later:
  
  \[ \text{PSA} = 1.42 \text{ ng/mL} \]

- In the second patient, PSA levels were 0.23 ng/mL and 0.84 ng/mL respectively;

- In the third patient, PSA levels were 0.16 ng/mL and 0.25 ng/mL respectively;

- In the fourth patient, PSA levels were 0.50 ng/mL and 0.77 ng/mL respectively;

- In the fifth patient, PSA levels were 0.24 ng/mL and 0.47 ng/mL respectively.

Due to the continuing biochemical progression and negative scan of the $[^{99mTc}]$Tc-PSMA-T4 study, the results in these cases were interpreted as false-negative images. In all patients in this group, the baseline PSA was less than or equal to 0.50 ng/mL.

Sensitivity of SPECT-CT study with $[^{99mTc}]$Tc-PSMA-T4 for imaging of recurrent prostate cancer in 36 involved patients was 84.37% (27/32), specificity — 100% (4/4) and accuracy — 86.11% (31/36).

For the clinical application of this study, the following could be summarized:

1. SPECT-CT imaging with $[^{99mTc}]$Tc-PSMA-T4 could be applied in patients with prostate cancer and biochemical progression if PSA $\geq 0.50$ ng/mL for the diagnosis of recurrent disease to determine personalized treatment for each patient.

2. To follow-up of patients after complex therapy for restaging of the disease in cases with unclear and uncertain findings from other imaging methods.

3. For imaging of focal recurrence and/or metastases after therapy to perform target radiotherapy or SRT (salvage radiation therapy).

4. Specific uptake of this tracer, depicted by SPECT-CT images could have clinical importance of identifying and assessing PSMA expression before consideration of Radio Ligand Therapy (RLT) with $[^{177}Lu]$Lu-PSMA.
Figure 7A. M/79yr with prostate cancer, T3N0M0, G3, Gl = 10 (35 + 5). Radiotherapy (2017), androgen deprivation therapy, chemotherapy. PSA = 10.87 ng/mL (03/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed multiple osteosclerotic bone lesions, partially negative due to prior treatment; B. Bone scan performed 6 months previously with a positive result for bone metastases in the pelvis, Th12 and left shoulder. New enlarged mediastinal lymph nodes and enlarged left adrenal gland, significant for metastases, were visualized. Disease progression

Discussion

The first results for clinical application of radiolabelled PSMA were published in 2013 [5] and this led to a qualitatively new nuclear medicine approach to this disease with the possibility of determining the optimal personalized therapy for patients [6, 10–12].

The cited sensitivity and specificity of the [68Ga]Ga-PSMA-11 studies are very high due to the better spatial resolution of the PET-CT camera [13]. Compared to them, the images obtained by SPECT camera are characterized by lower spatial resolution, which is significantly improved in the combined multimodal SPECT-CT devices with greatly increased quality of the obtained images [14].

The results received in the present prospective study of the clinical use of [99mTc]Tc-PSMA-T4 in recurrent prostate cancer are comparable to those cited in the scientific literature [13, 15]. In a large study of 225 patients reported by Schmidkonz et al. [15], it was found that the detection capabilities of prostate cancer with the biochemical progression of [99mTc]Tc-MIP-1404 SPECT-CT are comparable to those of [68Ga]Ga-PSMA PET-CT at levels of PSA > 2 ng/mL. At lower than these values and a smaller volume of the tumour tissue substrate, the sensitivity of SPECT-CT studies is reduced to 54% [16]. Liu et al. [17], report that at lower PSA values < 0.5 ng/mL the diagnostic value of [99mTc]HYNIC-PSMA SPECT-CT is 48.6%.

Another study showed that [99mTc]PSMA scanning was as sensitive as [68Ga]Ga-PSMA-11 in 28 prostate cancer patients in terms of visualization of bone and lymphogenic metastatic foci, with PSA levels > 2 ng/mL. SPECT-CT detection was lower when local recurrence was detected in the prostate bed in patients with evidence of biochemical progression with PSA < 0.5 ng/mL [15].

Goffin et al. [18], published data that the diagnostic value of SPECT-CT studies with [99mTc]Tc-MIP-1404 correlated with the degree of differentiation of the primary tumour — Gleason score. In patients at intermediate risk and high-risk disease with Gl ≥ 7 (3 + 4) detection rate reached 94% (86% for MRT), for visualization
of metastatic lymph nodes, the sensitivity and specificity were 90% and 67% respectively [18].

In patients with treated skeletal metastases and a negative \[^{99m}Tc\]Tc-PSMA(I&T) scan without lymphogenic and visceral secondary lesions, but with a progressive PSA elevation, control whole-body bone scintigraphy or follow-up by other standard visual methods is recommended. It would be appropriate to discuss the possibility of treatment with Xofigo in these patients [19].

Another clinical application of \[^{99m}Tc\]PSMA SPECT-CT, which is not discussed in the present study but is cited in recently published scientific articles, is the introduction of this method for selective radio-guided surgery of metastatic lymph nodes and/or local recurrence in the bed of the prostate. Initial data are very encouraging for the future use of a gamma probe for intraoperative detection of metastatic foci in the pelvis, previously imaged by SPECT-CT using \[^{99m}Tc\]Tc-PSMA(I&T) and \[^{99m}Tc\]Tc-PSMA-ALUG [20, 21].
Figure 9A. M/75yr with prostate cancer, pT2cN0M0, G2, Gl = 7 (4 + 3). Radical prostatectomy, radiotherapy (2015) and androgen deprivation therapy. PSA = 0.57 ng/mL (03/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed local recurrence in the prostate bed and enlarged single perirectal lymph node on the left with intensive tracer uptake; B. Gross tumour volume (GTV) and Clinical Tumour Volume (CTV) delineation based on the [99mTc]Tc-PSMA-T4 imaging results in radiotherapy planning. Radiation dose distribution in the region of the local recurrence and the single enlarge perirectal lymph node on the left in the same patient.
Figure 10. M/75yr with prostate cancer, pT2cN0M0, Gl = 7 (4 + 3). Radical prostatectomy/2016/ PSA = 0.36 ng/mL (02.2019) Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed enlarged single iliac lymph node on the left with intensive tracer uptake. Gross tumour volume (GTV) and Clinical Tumour Volume (CTV) delineation based on the [99mTc]Tc-PSMA-T4 imaging results in radiotherapy planning. Radiation dose distribution in the region of the single enlarged iliac lymph node on the left in the same patient. The PSA value decreased to 0.05 ng/mL (м.10.2019) after radiotherapy.

Conclusions

Based on these results and the review of the published literature, it could be summarized that the new [99mTc]Tc-PSMA-T4 tracer was shown to have favourable biodistribution and kinetic behaviour. This radiopharmaceutical can be prepared in a short time, technically easy to perform radiolabelling and quality control, with a significantly lower radiation dose for the patient. A whole-body scan with subsequent SPECT-CT imaging is recommended within one to three hours after intravenous administration.

The use of [99mTc]Tc-PSMA-T4 is a very good alternative as a diagnostic method in patients with prostate cancer in nuclear medicine centres that cannot produce [68Ga]Ga-PSMA.

SPECT-CT study with [99mTc]Tc-PSMA-T4 is a promising imaging tool showing high sensitivity and specificity with great diagnostic potential in patients with recurrent prostate cancer due to intensive target uptake in the local relapse of the prostate gland, lymphatic, bone and visceral metastases with a high diagnostic accuracy of 86.11%. These parameters make [99mTc]Tc-PSMA-T4 SPECT-CT studies an advanced visual method, cost-effective and widely applicable.

Conflict of interest

The authors report no conflicts of interest.

References


